Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
To the Editor: In the United States, there are approximately 3.2 million people—1.2% of the population—with a diagnosis of schizophrenia. While this percentage only represents a small fraction of the total population, it is estimated that one-third of these individuals have treatment-resistant schizophrenia. Although clozapine is the only US Food and Drug Administration (FDA)-approved antipsychotic for treatment-resistant schizophrenia, its use is limited by its unique and rather intimidating side effect profile, including agranulocytosis (incidence of approximately 1%) and myocarditis (incidence of approximately 3%).
Free Access: Please Log In
This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.
Please sign in or purchase this PDF for $40.00.